

Jing Zhang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4146374/publications.pdf>

Version: 2024-02-01

135
papers

12,729
citations

26567

56
h-index

24915

109
g-index

136
all docs

136
docs citations

136
times ranked

13554
citing authors

#	ARTICLE	IF	CITATIONS
1	Blood extracellular vesicles carrying synaptic function and brain-related proteins as potential biomarkers for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2023, 19, 909-923.	0.4	21
2	Astrocytic VEGFA: An essential mediator in blood-brain barrier disruption in Parkinson's disease. <i>Glia</i> , 2022, 70, 337-353.	2.5	44
3	Î±-Synuclein-containing erythrocytic extracellular vesicles: essential contributors to hyperactivation of monocytes in Parkinson's disease. <i>Journal of Neuroinflammation</i> , 2022, 19, 53.	3.1	17
4	Parkinson's Disease Derived Exosomes Aggravate Neuropathology in SNCA ^{A53T} Mice. <i>Annals of Neurology</i> , 2022, 92, 230-245.	2.8	19
5	Reduced erythrocytic CHCHD2 mRNA is associated with brain pathology of Parkinson's disease. <i>Acta Neuropathologica Communications</i> , 2021, 9, 37.	2.4	8
6	Development of a Sensitive Diagnostic Assay for Parkinson Disease Quantifying Î±-Synuclein-Containing Extracellular Vesicles. <i>Neurology</i> , 2021, 96, e2332-e2345.	1.5	18
7	Coniferaldehyde attenuates Alzheimer's pathology via activation of Nrf2 and its targets. <i>Theranostics</i> , 2020, 10, 179-200.	4.6	37
8	Immunoregulation of microglial polarization: an unrecognized physiological function of Î±-synuclein. <i>Journal of Neuroinflammation</i> , 2020, 17, 272.	3.1	22
9	Reduced oligodendrocyte exosome secretion in multiple system atrophy involves SNARE dysfunction. <i>Brain</i> , 2020, 143, 1780-1797.	3.7	66
10	Erythrocytic Î±-synuclein contained in microvesicles regulates astrocytic glutamate homeostasis: a new perspective on Parkinson's disease pathogenesis. <i>Acta Neuropathologica Communications</i> , 2020, 8, 102.	2.4	26
11	Phosphoproteomic and Kinomic Signature of Clinically Aggressive Grade I (1.5) Meningiomas Reveals RB1 Signaling as a Novel Mediator and Biomarker. <i>Clinical Cancer Research</i> , 2020, 26, 193-205.	3.2	6
12	Antibody-based methods for the measurement of Î±-synuclein concentration in human cerebrospinal fluid: method comparison and round robin study. <i>Journal of Neurochemistry</i> , 2019, 149, 126-138.	2.1	44
13	Extracellular microvesicles-derived from microglia treated with unaggregated Î±-synuclein attenuate mitochondrial fission and toxicity-induced by Parkinsonian toxin MPP+. <i>Biochemical and Biophysical Research Communications</i> , 2019, 517, 642-647.	1.0	13
14	Fine Particulate Matter Exposure and Cerebrospinal Fluid Markers of Vascular Injury. <i>Journal of Alzheimer's Disease</i> , 2019, 71, 1015-1025.	1.2	14
15	New windows into the brain: Central nervous system-derived extracellular vesicles in blood. <i>Progress in Neurobiology</i> , 2019, 175, 96-106.	2.8	121
16	Erythrocytic Î±-Synuclein as a potential biomarker for Parkinson's disease. <i>Translational Neurodegeneration</i> , 2019, 8, 15.	3.6	65
17	Impact of Pre-Analytical Differences on Biomarkers in the ADNI and PPMI Studies: Implications in the Era of Classifying Disease Based on Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 263-276.	1.2	13
18	Mass spectrometry: A platform for biomarker discovery and validation for Alzheimer's and Parkinson's diseases. <i>Journal of Neurochemistry</i> , 2019, 151, 397-416.	2.1	34

#	ARTICLE	IF	CITATIONS
19	Combining clinical and biofluid markers for early Parkinson's disease detection. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 109-114.	1.7	10
20	A Longitudinal Study of Total and Phosphorylated α -Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2018, 61, 1541-1553.	1.2	29
21	Kinome and phosphoproteome of high-grade meningiomas reveal AKAP12 as a central regulator of aggressiveness and its possible role in progression. <i>Scientific Reports</i> , 2018, 8, 2098.	1.6	42
22	Plasma α -synuclein and cognitive impairment in the Parkinson's Associated Risk Syndrome: A pilot study. <i>Neurobiology of Disease</i> , 2018, 116, 53-59.	2.1	29
23	Cerebrospinal fluid α -synuclein contributes to the differential diagnosis of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 1052-1062.	0.4	34
24	The Transport Mechanism of Extracellular Vesicles at the Blood-Brain Barrier. <i>Current Pharmaceutical Design</i> , 2018, 23, 6206-6214.	0.9	177
25	Mass-Spectrometry-Based Method To Quantify in Parallel Tau and Amyloid β^{1-42} in CSF for the Diagnosis of Alzheimer's Disease. <i>Journal of Proteome Research</i> , 2017, 16, 1228-1238.	1.8	30
26	An α -synuclein MRM assay with diagnostic potential for Parkinson's disease and monitoring disease progression. <i>Proteomics - Clinical Applications</i> , 2017, 11, 1700045.	0.8	9
27	A user's guide for α -synuclein biomarker studies in biological fluids: Perianalytical considerations. <i>Movement Disorders</i> , 2017, 32, 1117-1130.	2.2	54
28	Parkinson's disease biomarkers: perspective from the NINDS Parkinson's Disease Biomarkers Program. <i>Biomarkers in Medicine</i> , 2017, 11, 451-473.	0.6	49
29	Transmission of α -synuclein-containing erythrocyte-derived extracellular vesicles across the blood-brain barrier via adsorptive mediated transcytosis: another mechanism for initiation and progression of Parkinson's disease?. <i>Acta Neuropathologica Communications</i> , 2017, 5, 71.	2.4	188
30	Cerebrospinal fluid biomarkers for Alzheimer's and vascular disease vary by age, gender, and APOE genotype in cognitively normal adults. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 48.	3.0	38
31	Salivary total α -synuclein, oligomeric α -synuclein and SNCA variants in Parkinson's disease patients. <i>Scientific Reports</i> , 2016, 6, 28143.	1.6	55
32	Preliminary Study of Plasma Exosomal Tau as a Potential Biomarker for Chronic Traumatic Encephalopathy. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 1099-1109.	1.2	146
33	CNS tau efflux via exosomes is likely increased in Parkinson's disease but not in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2016, 12, 1125-1131.	0.4	154
34	Tau Proteins Cross the Blood-Brain Barrier. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 411-419.	1.2	50
35	Transcriptomic Profiling of Extracellular RNAs Present in Cerebrospinal Fluid Identifies Differentially Expressed Transcripts in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2016, 6, 109-117.	1.5	40
36	Identification of a specific α -synuclein peptide (α -Syn 29-40) capable of eliciting microglial superoxide production to damage dopaminergic neurons. <i>Journal of Neuroinflammation</i> , 2016, 13, 158.	3.1	21

#	ARTICLE	IF	CITATIONS
37	Alpha-Synuclein as a Biomarker for Parkinson's Disease. <i>Brain Pathology</i> , 2016, 26, 410-418.	2.1	217
38	Mortalin is Expressed by Astrocytes and Decreased in the Midbrain of Parkinson's Disease Patients. <i>Brain Pathology</i> , 2016, 26, 75-81.	2.1	18
39	Increased CSF E-Selectin in Clinical Alzheimer's Disease without Altered CSF A β 42 and Tau. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 883-887.	1.2	15
40	Cerebrospinal fluid A β 42 levels and APP processing pathway genes in Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 936-944.	2.2	14
41	Identification of Synaptosomal Proteins Binding to Monomeric and Oligomeric α -Synuclein. <i>PLoS ONE</i> , 2015, 10, e0116473.	1.1	63
42	Cerebrospinal Fluid Particles in Alzheimer Disease and Parkinson Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2015, 74, 672-687.	0.9	33
43	Astrocytic Dynamin-Like Protein 1 Regulates Neuronal Protection against Excitotoxicity in Parkinson Disease. <i>American Journal of Pathology</i> , 2015, 185, 536-549.	1.9	27
44	Diagnostic Values of Cerebrospinal Fluid T-Tau and A β 42 using Meso Scale Discovery Assays for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 709-719.	1.2	28
45	Biofluid Biomarkers of Mild Traumatic Brain Injury. <i>JAMA Neurology</i> , 2015, 72, 1103.	4.5	13
46	Group comparison of spatiotemporal dynamics of intrinsic networks in Parkinson's disease. <i>Brain</i> , 2015, 138, 2672-2686.	3.7	24
47	Biomarkers of Parkinson's Disease. <i>Biomarkers in Disease</i> , 2015, , 1009-1030.	0.0	0
48	P2X7 receptor is critical in α -synuclein-mediated microglial NADPH oxidase activation. <i>Neurobiology of Aging</i> , 2015, 36, 2304-2318.	1.5	94
49	Phosphorylated α -synuclein in Parkinson's disease: correlation depends on disease severity. <i>Acta Neuropathologica Communications</i> , 2015, 3, 7.	2.4	74
50	Fluid biomarkers in multiple system atrophy: A review of the MSA Biomarker Initiative. <i>Neurobiology of Disease</i> , 2015, 80, 29-41.	2.1	71
51	Cerebrospinal Fluid Peptides as Potential Parkinson Disease Biomarkers: A Staged Pipeline for Discovery and Validation*. <i>Molecular and Cellular Proteomics</i> , 2015, 14, 544-555.	2.5	51
52	Proteomic profiling in MPTP monkey model for early Parkinson disease biomarker discovery. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2015, 1854, 779-787.	1.1	25
53	CSF tau and tau/A β 42 predict cognitive decline in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 271-276.	1.1	81
54	α -Synuclein, a chemoattractant, directs microglial migration via H α -dependent Lyn phosphorylation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E1926-35.	3.3	123

#	ARTICLE	IF	CITATIONS
55	Time-Resolved Proteomic Visualization of Dendrimer Cellular Entry and Trafficking. <i>Journal of the American Chemical Society</i> , 2015, 137, 12772-12775.	6.6	18
56	Cerebral perfusion and cortical thickness indicate cortical involvement in mild Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1893-1900.	2.2	42
57	Blood $\hat{\pm}$ -synuclein in agricultural pesticide handlers in central Washington State. <i>Environmental Research</i> , 2015, 136, 75-81.	3.7	6
58	Cerebrospinal Fluid $\hat{\pm}$ -Synuclein Predicts Cognitive Decline in Parkinson Disease Progression in the DATATOP Cohort. <i>American Journal of Pathology</i> , 2014, 184, 966-975.	1.9	126
59	Targeted Discovery and Validation of Plasma Biomarkers of Parkinson's Disease. <i>Journal of Proteome Research</i> , 2014, 13, 4535-4545.	1.8	30
60	Alpha synuclein is transported into and out of the brain by the blood-brain barrier. <i>Peptides</i> , 2014, 62, 197-202.	1.2	138
61	Cerebrospinal Fluid $\hat{\pm}$ -Synuclein and Lewy Body-Like Symptoms in Normal Controls, Mild Cognitive Impairment, and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 43, 1007-1016.	1.2	27
62	Plasma exosomal $\hat{\pm}$ -synuclein is likely CNS-derived and increased in Parkinson's disease. <i>Acta Neuropathologica</i> , 2014, 128, 639-650.	3.9	504
63	Proteomic Analysis of Saliva from Patients with Oral Chronic Graft-Versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1048-1055.	2.0	35
64	Cheek cell-derived $\hat{\pm}$ -synuclein and DJ-1 do not differentiate Parkinson's disease from control. <i>Neurobiology of Aging</i> , 2014, 35, 418-420.	1.5	30
65	Low levels of cerebrospinal fluid complement 3 and factor H predict faster cognitive decline in mild cognitive impairment. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 36.	3.0	26
66	Biomarkers of Parkinson's Disease. , 2014, , 1-18.		0
67	Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease. <i>Acta Neuropathologica</i> , 2013, 126, 671-682.	3.9	76
68	CSF $\hat{\pm}$ -synuclein improves diagnostic and prognostic performance of CSF tau and $\hat{\Delta}^2$ in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2013, 126, 683-697.	3.9	90
69	Biomarkers of Parkinson's disease: current status and future perspectives. <i>Drug Discovery Today</i> , 2013, 18, 155-162.	3.2	52
70	An Update on CSF Biomarkers of Parkinson's Disease. <i>Advances in Predictive, Preventive and Personalised Medicine</i> , 2013, , 161-184.	0.6	5
71	$\hat{\pm}$ -Synuclein in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2013, 36, 679-688.	1.2	74
72	Effects of Baseline CSF $\hat{\pm}$ -Synuclein on Regional Brain Atrophy Rates in Healthy Elders, Mild Cognitive Impairment and Alzheimer's Disease. <i>PLoS ONE</i> , 2013, 8, e85443.	1.1	16

#	ARTICLE	IF	CITATIONS
73	Phosphorylated α -Synuclein in Parkinson's Disease. <i>Science Translational Medicine</i> , 2012, 4, 121ra20.	5.8	223
74	DJ-1 isoforms in whole blood as potential biomarkers of Parkinson disease. <i>Scientific Reports</i> , 2012, 2, 954.	1.6	90
75	Applying bioinformatics to proteomics: Is machine learning the answer to biomarker discovery for PD and MSA?. <i>Movement Disorders</i> , 2012, 27, 1595-1597.	2.2	9
76	DJ-1 and α -SYN in LRRK2 CSF do not correlate with striatal dopaminergic function. <i>Neurobiology of Aging</i> , 2012, 33, 836.e5-836.e7.	1.5	34
77	Premotor biomarkers for Parkinson's disease - a promising direction of research. <i>Translational Neurodegeneration</i> , 2012, 1, 11.	3.6	54
78	Biochemical premotor biomarkers for Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 644-650.	2.2	37
79	Mortalin in Neurological Diseases. , 2012, , 139-158.		0
80	Complement 3 and Factor H in Human Cerebrospinal Fluid in Parkinson's Disease, Alzheimer's Disease, and Multiple-System Atrophy. <i>American Journal of Pathology</i> , 2011, 178, 1509-1516.	1.9	97
81	Cerebrospinal fluid biomarkers and cognitive performance in non-demented patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 61-64.	1.1	64
82	The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. <i>Alzheimer's and Dementia</i> , 2011, 7, 386.	0.4	354
83	CSF α -synuclein, tau, and amyloid β in Parkinson's disease. <i>Lancet Neurology</i> , The, 2011, 10, 681.	4.9	15
84	Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. <i>Annals of Neurology</i> , 2011, 69, 570-580.	2.8	371
85	Salivary α -synuclein and DJ-1: potential biomarkers for Parkinson's disease. <i>Brain</i> , 2011, 134, e178-e178.	3.7	196
86	Salivary Tau Species are Potential Biomarkers of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 27, 299-305.	1.2	153
87	Glycoproteomics in neurodegenerative diseases. <i>Mass Spectrometry Reviews</i> , 2010, 29, 79-125.	2.8	99
88	CSF α -synuclein and tau in Parkinson's disease with cognitive impairment. <i>Movement Disorders</i> , 2010, 25, 2682-2685.	2.2	162
89	Identification of ciliary neurotrophic factor receptor α as a mediator of neurotoxicity induced by α -synuclein. <i>Proteomics</i> , 2010, 10, 2138-2150.	1.3	12
90	Biomarkers for Cognitive Impairment in Parkinson Disease. <i>Brain Pathology</i> , 2010, 20, 660-671.	2.1	33

#	ARTICLE	IF	CITATIONS
91	SNCA Variant Associated With Parkinson Disease and Plasma α -Synuclein Level. Archives of Neurology, 2010, 67, 1350-6.	4.9	157
92	Using α -omics TM to define pathogenesis and biomarkers of Parkinson TM s disease. Expert Review of Neurotherapeutics, 2010, 10, 925-942.	1.4	71
93	DJ-1 and α -synuclein in human cerebrospinal fluid as biomarkers of Parkinson TM s disease. Brain, 2010, 133, 713-726.	3.7	575
94	Quantitative Proteomic Analysis of Oligodendrogliomas With and Without 1p/19q Deletion. Journal of Proteome Research, 2010, 9, 2610-2618.	1.8	12
95	Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Neuroscience Letters, 2010, 480, 78-82.	1.0	184
96	Rab11a and HSP90 Regulate Recycling of Extracellular α -Synuclein. Journal of Neuroscience, 2009, 29, 1480-1485.	1.7	128
97	Biomarker discovery in neurodegenerative diseases: A proteomic approach. Neurobiology of Disease, 2009, 35, 157-164.	2.1	102
98	A role for a novel protein, nucleolin, in Parkinson's disease. Neuroscience Letters, 2009, 459, 11-15.	1.0	39
99	Mass Spectrometry Based Targeted Protein Quantification: Methods and Applications. Journal of Proteome Research, 2009, 8, 787-797.	1.8	349
100	Identification of Glutathione S-Transferase Pi as a Protein Involved in Parkinson Disease Progression. American Journal of Pathology, 2009, 175, 54-65.	1.9	75
101	Identification of proteins in human substantia nigra. Proteomics - Clinical Applications, 2008, 2, 776-782.	0.8	33
102	Proteomic identification of proteins in the human brain: Towards a more comprehensive understanding of neurodegenerative disease. Proteomics - Clinical Applications, 2008, 2, 1484-1497.	0.8	20
103	Proteomics of Human Neurodegenerative Diseases. Journal of Neuropathology and Experimental Neurology, 2008, 67, 923-932.	0.9	31
104	Predominant Release of Lysosomal Enzymes by Newborn Rat Microglia After LPS Treatment Revealed by Proteomic Studies. Journal of Proteome Research, 2008, 7, 2033-2049.	1.8	34
105	Application of Targeted Quantitative Proteomics Analysis in Human Cerebrospinal Fluid Using a Liquid Chromatography Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Tandem Mass Spectrometer (LC MALDI TOF/TOF) Platform. Journal of Proteome Research, 2008, 7, 720-730.	1.8	67
106	CSF Multianalyte Profile Distinguishes Alzheimer and Parkinson Diseases. American Journal of Clinical Pathology, 2008, 129, 526-529.	0.4	248
107	Mortalin: A Protein Associated With Progression of Parkinson Disease?. Journal of Neuropathology and Experimental Neurology, 2008, 67, 117-124.	0.9	77
108	Biomarkers for Alzheimer TM s disease. Expert Review of Neurotherapeutics, 2007, 7, 1021-1028.	1.4	14

#	ARTICLE	IF	CITATIONS
109	Proteomics Identification of Proteins in Human Cortex Using Multidimensional Separations and MALDI Tandem Mass Spectrometer. <i>Molecular and Cellular Proteomics</i> , 2007, 6, 1818-1823.	2.5	44
110	Identification of Novel Proteins Associated with Both α -Synuclein and DJ-1. <i>Molecular and Cellular Proteomics</i> , 2007, 6, 845-859.	2.5	153
111	Oligomeric α -synuclein inhibits tubulin polymerization. <i>Biochemical and Biophysical Research Communications</i> , 2007, 356, 548-553.	1.0	86
112	Identification of Proteins Involved in Microglial Endocytosis of α -Synuclein. <i>Journal of Proteome Research</i> , 2007, 6, 3614-3627.	1.8	64
113	Microglial PHOX and Mac-1 are essential to the enhanced dopaminergic neurodegeneration elicited by A30P and A53T mutant alpha-synuclein. <i>Glia</i> , 2007, 55, 1178-1188.	2.5	147
114	Proteomics of human cerebrospinal fluid – the good, the bad, and the ugly. <i>Proteomics - Clinical Applications</i> , 2007, 1, 805-819.	0.8	48
115	A combined dataset of human cerebrospinal fluid proteins identified by multi-dimensional chromatography and tandem mass spectrometry. <i>Proteomics</i> , 2007, 7, 469-473.	1.3	111
116	Proteomic Identification of Novel Proteins in Cortical Lewy Bodies. <i>Brain Pathology</i> , 2007, 17, 139-145.	2.1	194
117	Identification of novel proteins affected by rotenone in mitochondria of dopaminergic cells. <i>BMC Neuroscience</i> , 2007, 8, 67.	0.8	45
118	Characterization of Proteome of Human Cerebrospinal Fluid. <i>International Review of Neurobiology</i> , 2006, 73, 29-98.	0.9	28
119	Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. <i>Journal of Alzheimer's Disease</i> , 2006, 9, 293-348.	1.2	362
120	Proteomic biomarker discovery in cerebrospinal fluid for neurodegenerative diseases. <i>Journal of Alzheimer's Disease</i> , 2006, 8, 377-386.	1.2	55
121	Proteomic analysis of microglial contribution to mouse strain-dependent dopaminergic neurotoxicity. <i>Glia</i> , 2006, 53, 567-582.	2.5	56
122	Proteomic Identification of a Stress Protein, Mortalin/mthsp70/GRP75. <i>Molecular and Cellular Proteomics</i> , 2006, 5, 1193-1204.	2.5	220
123	Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. <i>Journal of Alzheimer's Disease</i> , 2005, 7, 125-133.	1.2	160
124	Proteomic determination of widespread detergent insolubility, including $A\beta$ but not tau, early in the pathogenesis of Alzheimer's disease. <i>FASEB Journal</i> , 2005, 19, 1923-1925.	0.2	46
125	Microglial Activation Induced by Neurodegeneration. <i>Molecular and Cellular Proteomics</i> , 2005, 4, 1471-1479.	2.5	71
126	Proteomic analysis of neurofibrillary tangles in Alzheimer disease identifies GAPDH as a detergent-insoluble paired helical filament tau binding protein. <i>FASEB Journal</i> , 2005, 19, 1-12.	0.2	172

#	ARTICLE	IF	CITATIONS
127	Quantitative proteomic analysis of mitochondrial proteins: relevance to Lewy body formation and Parkinson's disease. <i>Molecular Brain Research</i> , 2005, 134, 119-138.	2.5	126
128	Quantitative proteomic analysis of age-related changes in human cerebrospinal fluid. <i>Neurobiology of Aging</i> , 2005, 26, 207-227.	1.5	162
129	Aggregated α -synuclein activates microglia: a process leading to disease progression in Parkinson's disease. <i>FASEB Journal</i> , 2005, 19, 533-542.	0.2	1,065
130	Analysis of α -Synuclein-associated Proteins by Quantitative Proteomics. <i>Journal of Biological Chemistry</i> , 2004, 279, 39155-39164.	1.6	149
131	Manganese ethylene-bis-dithiocarbamate and selective dopaminergic neurodegeneration in rat: a link through mitochondrial dysfunction. <i>Journal of Neurochemistry</i> , 2003, 84, 336-346.	2.1	201
132	Catalysis of catechol oxidation by metal-dithiocarbamate complexes in pesticides. <i>Free Radical Biology and Medicine</i> , 2002, 33, 1714-1723.	1.3	87
133	Enhancement of Dopaminergic Neurotoxicity by the Mercapturate of Dopamine. <i>Journal of Neurochemistry</i> , 2000, 74, 970-978.	2.1	28
134	Parkinson's Disease Is Associated with Oxidative Damage to Cytoplasmic DNA and RNA in Substantia Nigra Neurons. <i>American Journal of Pathology</i> , 1999, 154, 1423-1429.	1.9	570
135	Secondary Excitotoxicity Contributes to Dopamine-Induced Apoptosis of Dopaminergic Neuronal Cultures. <i>Biochemical and Biophysical Research Communications</i> , 1998, 248, 812-816.	1.0	51